Quantitative brain T1 maps derived from T1-weighted MRI acquisitions: a proof-of-concept study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SpringerOpen Country of Publication: England NLM ID: 101721752 Publication Model: Electronic Cited Medium: Internet ISSN: 2509-9280 (Electronic) Linking ISSN: 25099280 NLM ISO Abbreviation: Eur Radiol Exp Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London, United Kingdom] : SpringerOpen, [2017]-
    • Subject Terms:
      Phantoms, Imaging* ; Magnetic Resonance Imaging*/methods ; Brain Neoplasms*/diagnostic imaging ; Brain Neoplasms*/secondary ; Proof of Concept Study* ; Contrast Media*; Humans ; Male ; Female ; Adult ; Imaging, Three-Dimensional/methods ; Middle Aged ; Brain/diagnostic imaging
    • Abstract:
      Background: Longitudinal T1 relaxation time is a key imaging biomarker. In addition, T1 values are modulated by the administration of T1 contrast agents used in patients with tumors and metastases. However, in clinical practice, dedicated T1 mapping sequences are often not included in brain MRI protocols. The aim of this study is to address the absence of dedicated T1 mapping sequences in imaging protocol by deriving T1 maps from standard T1-weighted sequences.
      Methods: A phantom, composed of 144 solutions of paramagnetic agents at different concentrations, was imaged with a three-dimensional (3D) T1-weighed turbo spin-echo (TSE) sequence designed for brain imaging. The relationship between the T1 values and the signal intensities was established using this phantom acquisition. T1 mapping derived from 3D T1-weighted TSE acquisitions in four healthy volunteers and one patient with brain metastases were established and compared to reference T1 mapping technique. The concentration of Gd-based contrast agents in brain metastases were assessed from the derived T1 maps.
      Results: Based on the phantom acquisition, the relationship between T1 values and signal intensity (SI) was found equal to T1 = 0.35 × SI - 1.11 (R 2  = 0.97). TSE-derived T1 values measured in white matter and gray matter in healthy volunteers were equal to 0.997 ± 0.096 s and 1.358 ± 0.056 s (mean ± standard deviation), respectively. Mean Gd 3+ concentration value in brain metastases was 94.7 ± 30.0 μM.
      Conclusion: The in vivo results support the relevance of the phantom-based approach: brain T1 maps can be derived from T1-weighted acquisitions.
      Relevance Statement: High-resolution brain T1 maps can be generated, and contrast agent concentration can be quantified and imaged in brain metastases using routine 3D T1-weighted TSE acquisitions.
      Key Points: Quantitative T1 mapping adds significant value to MRI diagnostics. T1 measurement sequences are rarely included in routine protocols. T1 mapping and concentration of contrast agents can be derived from routine standard scans. The diagnostic value of MRI can be improved without additional scan time.
      (© 2024. The Author(s).)
    • References:
      Eur Radiol. 2022 Jul;32(7):4521-4526. (PMID: 35118530)
      Magn Reson Med Sci. 2008;7(1):13-21. (PMID: 18460844)
      J Neuroradiol. 2020 Sep;47(5):358-368. (PMID: 32017974)
      Magn Reson Med. 2015 Feb;73(2):514-22. (PMID: 24578189)
      Neuroimage. 2010 Jun;51(2):512-20. (PMID: 20211271)
      Eur Radiol Exp. 2018 Dec 19;2(1):45. (PMID: 30569375)
      Eur Radiol. 2019 Jul;29(7):3467-3479. (PMID: 30972545)
      Magn Reson Med. 2009 Apr;61(4):899-906. (PMID: 19195021)
      Eur Radiol. 2016 Jun;26(6):1818-25. (PMID: 26334511)
      Invest Radiol. 2023 May 1;58(5):314-319. (PMID: 36729811)
      Magn Reson Med. 2021 Sep;86(3):1194-1211. (PMID: 33847012)
      Radiother Oncol. 2021 Jul;160:159-165. (PMID: 33961915)
      Magn Reson Med. 1988 May;7(1):23-34. (PMID: 3386519)
      Neuroimage. 2010 Jan 15;49(2):1271-81. (PMID: 19819338)
      Invest Radiol. 2021 Mar 1;56(3):163-172. (PMID: 32858581)
      Sci Adv. 2020 Jul 15;6(29):eaay5279. (PMID: 32832613)
      Magn Reson Med. 2011 Apr;65(4):1036-42. (PMID: 21413067)
      Eur Radiol Exp. 2023 Oct 13;7(1):61. (PMID: 37833469)
      J Magn Reson Imaging. 2023 Jul;58(1):313-323. (PMID: 36315197)
      AJNR Am J Neuroradiol. 2003 Jan;24(1):58-67. (PMID: 12533328)
      AJNR Am J Neuroradiol. 2019 Jul;40(7):1140-1148. (PMID: 31221635)
      Angew Chem Int Ed Engl. 2011 Dec 16;50(51):12299-303. (PMID: 22057640)
    • Contributed Indexing:
      Keywords: Brain; Brain neoplasms; Contrast media; Magnetic resonance imaging; T1 mapping
    • Accession Number:
      0 (Contrast Media)
    • Publication Date:
      Date Created: 20241008 Date Completed: 20241008 Latest Revision: 20241011
    • Publication Date:
      20241011
    • Accession Number:
      PMC11461398
    • Accession Number:
      10.1186/s41747-024-00517-2
    • Accession Number:
      39377962